New funding for target discovery related to SynGAP1-associated non-syndromic intellectual disability
We are excited to be starting a new project on SynGAP thanks to support from Leon & friends e.V.
SynGAP is a protein that reduces the activity of Ras-GTPases, which are important in regulating the ERK group of MAP kinases and synaptic connectivity. Mutations in the SynGAP1-gene can cause a non-syndromic intellectual disability (NSID) disorder that often includes epilepsy. Our project aims to make use of our recently developed high-throughout physiology pipeline to identify RasGEF proteins, the RasGTPase activators, that counteract the neuronal signalling affected by reduced SynGAP levels. These RasGEFs could potentially be druggable targets relevant for drug discovery approaches to treat SynGAP-associated NSID.
Recent Posts
- Christel Sourander Successfully Defends Her Thesis Christel Sourander successfully defended her thesis: “Identifying the effect of JNK on neural activity and Read moreSeptember 9, 2025
- Researchers at Åbo Akademi University Discover a New Molecular Switch Regulating Breast Cancer Progression A research group led by our our affiliated group leader Professor Lea Sistonen at Åbo Read moreSeptember 4, 2025
- Autumn 2025 Frontiers of Science seminars start soon Frontiers of Science is a long-running seminar series, celebrating over 25 years of bringing internationally Read moreSeptember 3, 2025
- The Elias Tillandz Prize to Turku Bioscience Researchers The Elias Tillandz Prize for the Best Scientific Publication of 2024 was presented for two Read moreSeptember 2, 2025
- Registration to FFGC Sequencing day is open! Registration to FFGC Sequencing day is open! The event is organized by Finnish Functional Genomics Read moreAugust 27, 2025
- Dr. Inna Starskaia received a three-year training award from Breakthrough T1D Dr. Inna Starskaia has been awarded a prestigious three-year training award from Breakthrough T1D, the Read moreAugust 22, 2025